Altamira Therapeutics Ltd. · OTC:CYTOF

Altamira Therapeutics — Auris Medical Holding — Technical Presentation (September 2016)

12 slides from Altamira Therapeutics's technical presentation, Sep 19, 2016

  1. Slide 1: What is the safety profile of Intratympanic Injections?

    1 What is the safety profile of Intratympanic Injections? • Common procedure in ENT offices • Procedure is generally considered safe and routine ; Some old literature suggests increased risk of TM perforation • Commonly used for local, off - label administration of corticosteroids or gentamicin • Un

  2. Slide 2: Safety Data Collected in TACTT2 Trial

    2 Safety Data Collected in TACTT2 Trial • Efficacy and Safety of AM - 101 in the T reatment of Ac ute Peripheral T inni t us 2 ( TACTT2) • AM - 101 is a small molecule NMDA receptor antagonist formulated in hyaluronic acid and delivered via an intratympanic injection • Systematic collection of safet

  3. Slide 3: TACTT2 Trial Design Overview

    3 TACTT2 Trial Design Overview • Acute peripheral tinnitus following traumatic cochlear insult (acute noise trauma, barotrauma, surgery trauma) or otitis media • Up to 3 months from onset • Documented tinnitus history

  4. Slide 4: Patient Enrollment

    4 Assessed for eligibility (n=478) Withdrawal by subject (n=9) Lost to follow - up (n=5) Other reasons (n=2) Withdrawal due to AE (n=1) Allocated to AM - 101 (n=204) Received AM - 101 (n=201) / Safety analysis Allocation Analysis Follow - Up Enrollment Excluded (n=135) Randomized (n=343) Patient Enr

  5. Slide 5: Demographics and Baseline Characteristics

    5 Safety Population AM - 101 (n=201) Placebo (n=135) Total (n=336) Age (mean) 43.4 44.2 43.7 Age (range) 18 to 74 20 to 73 18 to 74 Time from tinnitus onset (mean in days) 64.8 64.6 64.7 Average hearing threshold (4, 6 and 8 kHz) 27.4 28.7 28.0 Tinnitus treatment laterality Unilateral 119 76 195 Bil

  6. Slide 6: Safety Endpoints

    6 Safety Endpoints • Primary: Average hearing deterioration of ≥15 dB from baseline to Day 35 in two contiguous frequencies • 15 dB considered as clinically relevant • Permanent threshold shift from intervention, if any, expected to show at Day 35 • Secondary: • Clinically relevant hearing deteriora

  7. Slide 7: Injection Procedure (Safety Population)

    Injection Procedure (Safety Population) 7 0% 20% 40% 60% 80% 100% Posterior- inferior Anterior- inferior Superior quadrants Mixed quadrants Quadrant for Injection AM-101 Placebo 83.0% 0.3% 11.3% 5.4% Treatment approach Tympanopuncture Tympanostomy tube Tympanotomy Different techniques used 0% 5% 10%

  8. Slide 8: Clinically Relevant Hearing Deterioration

    Clinically Relevant Hearing Deterioration 0% 5% 10% 15% 20% Day 10 Day 35 Day 84 Air Conduction AM-101 Placebo P=0.82 P=0.22 0% 5% 10% 15% 20% Day 10 Day 35 Day 84 Bone conduction AM-101 Placebo P=0.55 P=1.00 P=0.33 % of Patients with Hearing Deterioration • No difference between treated and untreat

  9. Slide 9: Adverse Events

    • All drug - related AEs were mild to moderate • Procedure - related AEs were predominantly transient and mild to moderate • All SAEs were isolated cases and not related to study drug or procedure • Low rate of procedure - related infections • AEs leading to withdrawal: – AM - 101: Subjective worsen

  10. Slide 10: Tympanic Membrane Closure

    Tympanic Membrane Closure • Rapid closure of tympanic membrane perforation following injection • Data confirmed results from previous Phase 2 trial Closure observed at follow - up visit on: AM - 101 Placebo Day 10 91.7% 93.1% Day 35 99.0% 99.2% Day 84 100.0% 100.0% 10

  11. Slide 11: Summary of TACTT2 Safety Results

    Summary of TACTT2 Safety Results • AM - 101 and intratympanic injection procedure were well tolerated • Over course of ~1 ,000 injections, no drug or procedure - related SAEs observed • Comparable drug - and procedure - related AE rate between AM - 101 and placebo • Low occurence of transient proced

  12. Slide 12: Acknowledgements

    12 Acknowledgements The authors would like to thank all investigators, study staff and patients who participated in the TACTT2 trial

Auris Medical Holding — Technical Presentation (September 2016) on 6ix